Physician profile
Stuart Fox
NPI 1063413102
$49,303.10
in general payments reported to CMS, 2019-2025
86 companies · $1,410 in 2025
The $1,410 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $9,458 · 2021: $8,417 · 2022: $2,382 · 2023: $2,375 · 2024: $1,975 · 2025: $1,410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,577 · Consulting Fee: $150 · Education: $34.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,576.52 |
| Consulting Fee | $150.00 |
| Education | $34.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $20,750.46 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Genentech USA, INC. | $11,510.37 | 2019-2024 | Ocrevus, Enspryng |
| Genzyme Corporation | $4,785.04 | 2019-2022 | |
| Abbvie INC. | $1,581.58 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,289.50 | 2019-2025 | |
| Biogen, INC. | $785.29 | 2019-2025 | Tysabri, Vumerity, Leqembi |
| Celgene Corporation | $466.08 | 2022-2025 | Zeposia |
| Pfizer INC. | $461.56 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $456.26 | 2019-2025 | Ultomiris, Soliris |
| Allergan, INC. | $453.16 | 2019-2022 | |
| Ucb, INC. | $414.98 | 2019-2025 | Briviact, Nayzilam |
| Csl Behring | $388.79 | 2019-2025 | Hizentra |
| Emd Serono, INC. | $369.32 | 2019-2024 | Mavenclad |
| Supernus Pharmaceuticals, INC. | $296.13 | 2019-2021 | |
| Amgen INC. | $276.87 | 2019-2025 | Uplizna |
Show all 86 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.